Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bordetella

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    78 result(s) found for: Bordetella. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2009-013411-36 Sponsor Protocol Number: VTdaP-01 Start Date*: 2009-12-08
    Sponsor Name:Statens Serum Institut
    Full Title: Immunogenicity and safety of a tetanus, diphtheria and mono component acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as a booster vaccination t...
    Medical condition: The intended use of the vaccine in this study is to increase the immunological protection against pertussis in adults who completed primary vaccination with diphtheria, tetanus and pertussis vaccin...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10034738 Pertussis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006124-64 Sponsor Protocol Number: 111815 (DTPA-IPV(BOOSTRIX-IPV)-010 Start Date*: 2009-02-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with S...
    Medical condition: Booster immunisation of healthy preschool children against diphtheria, tetanus, pertussis, poliomyelitis, mumps, measles and rubella; and first or second immunisation of healthy preschool children ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034738 LLT
    9.1 10013023 LLT
    9.1 10043376 LLT
    9.1 10036012 LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001119-38 Sponsor Protocol Number: 116945 Start Date*: 2015-09-21
    Sponsor Name:GlaxoSmithKline
    Full Title: A Phase IV, observer-blind, randomised, cross-over, placebo-controlled, multicentre study to assess the immunogenicity and safety of a single dose of Boostrix? in pregnant women.
    Medical condition: Booster immunisation against diphtheria, tetanus and pertussis diseases. The study population for this study will include pregnant women.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10047976 Whooping cough due to bordetella pertussis (B. pertussis) LLT
    18.0 100000004862 10009663 Clostridium tetani infection LLT
    18.0 100000004862 10054237 Corynebacterium diphtheriae infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) CZ (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000943-26 Sponsor Protocol Number: 115375 Start Date*: 2011-05-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open-label, study to assess the antibody persistence in healthy 5-year-old children, previously vaccinated at 3, 5 and 11months of age with GSK Biologicals’ DTPa-HBV-IPV/Hib or DTPa-IPV...
    Medical condition: Healthy volunteers (Immunogenicity of the DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccines in terms of persistence of antibodies to diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Hib vacc...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10043376 Tetanus PT
    13.1 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    13.1 10021881 - Infections and infestations 10034738 Pertussis PT
    13.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    13.1 10021881 - Infections and infestations 10013023 Diphtheria PT
    13.1 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2016-003678-42 Sponsor Protocol Number: IIV-316 Start Date*: 2017-09-01
    Sponsor Name:RIVM [...]
    1. RIVM
    2. Clinical Trials and Research Governance
    3. Turun Yliopisto
    Full Title: Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands...
    Medical condition: Pertussis infection
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005273-31 Sponsor Protocol Number: HPARSRSG12/06 Start Date*: 2013-05-30
    Sponsor Name:Public Health England
    Full Title: A phase III/IV randomised open-label study and comparison of the immunogenicity and safety of a single adolescent booster dose of a meningococcal group C conjugate-containing booster vaccine (Menin...
    Medical condition: Prevention of meningitis C and pertussis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10006021 Booster LLT
    14.1 10021881 - Infections and infestations 10028910 Neisseria meningitides meningitis LLT
    14.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    14.1 10042613 - Surgical and medical procedures 10069593 Pertussis immunization LLT
    14.1 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    16.0 10021881 - Infections and infestations 10027275 Meningococcal infection, unspecified LLT
    14.1 10021881 - Infections and infestations 10034738 Pertussis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012219-16 Sponsor Protocol Number: 113060 Start Date*: 2011-04-18
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open-label, non-randomised, multicentre study to assess the immunogenicity and reactogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, ...
    Medical condition: Booster immunisation of healthy adults against diphtheria, tetanus, pertussis and poliomyelitis.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10043376 Tetanus PT
    14.0 10021881 - Infections and infestations 10034738 Pertussis PT
    14.0 10021881 - Infections and infestations 10013023 Diphtheria PT
    14.0 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004056-36 Sponsor Protocol Number: Sched2 Start Date*: 2007-12-20
    Sponsor Name:Health Protection Agency
    Full Title: A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses ...
    Medical condition: All products arre vaccines and are given to healthy volunteers to induce immunological responses to provide protection against: Pediacel - tetanus, diphtheria, polio, pertussis (whooping cough), H...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027274 Meningococcal infection PT
    9.1 10061353 Pneumococcal infection LLT
    9.1 10013023 Diphtheria LLT
    9.1 10043376 Tetanus LLT
    9.1 10034738 Pertussis LLT
    9.1 10018955 Haemophilus meningitis LLT
    9.1 10036008 Polio LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002378-37 Sponsor Protocol Number: LIS/IMM138 Start Date*: 2008-12-23
    Sponsor Name:National Institute of Health and the Environment (RIVM)
    Full Title: The longitudinal kinetics of long term cellular memory immunity against Bordetella pertussis in Dutch 8-9 years old children after ACV booster vaccination.
    Medical condition: Whooping cough is a respiratory disease caused by Bordetella pertussis. Young infants are mostly at risk, but older children are the main source of infection. Since the incidence of whooping cough...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012460-14 Sponsor Protocol Number: 112980 Start Date*: 2010-05-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paed...
    Medical condition: Primary and booster immunisation of healthy infants in the first two years of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b, rotavirus and p...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10043376 Tetanus LLT
    12.1 10013023 Diphtheria LLT
    12.1 10034738 Pertussis LLT
    12.1 10019731 Hepatitis B LLT
    12.1 10036012 Poliomyelitis LLT
    12.1 10018952 Haemophilus influenzae infection LLT
    12.1 10067470 Rotavirus infection LLT
    12.1 10061353 Pneumococcal infection LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) GB (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016635-36 Sponsor Protocol Number: 113615 Start Date*: 2010-03-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given to healthy infants at 2,...
    Medical condition: Primary and booster immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b, serogroup C meningoc...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10043376 Tetanus LLT
    12.1 10013023 Diphtheria LLT
    12.1 10034738 Pertussis LLT
    12.1 10019731 Hepatitis B LLT
    12.1 10036012 Poliomyelitis LLT
    12.1 10018952 Haemophilus influenzae infection LLT
    12.1 10027274 Meningococcal infection LLT
    12.1 10067470 Rotavirus infection LLT
    12.1 10061353 Pneumococcal infection LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001117-41 Sponsor Protocol Number: 201330 Start Date*: 2015-11-13
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of Infanrix hexa? administered as primary vaccination in healthy infants born to mothers given Boo...
    Medical condition: Healthy volunteers [Primary immunisation of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b (Hib)].
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10006025 Bordetella pertussis laryngotracheobronchitis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) Outside EU/EEA FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000876-33 Sponsor Protocol Number: 114843 Start Date*: 2011-08-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, double-blind, multicentre study to evaluate the safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in heal...
    Medical condition: Healthy volunteers (toddlers): Booster immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10043376 Tetanus PT
    14.0 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    14.0 10021881 - Infections and infestations 10034738 Pertussis PT
    14.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.0 10021881 - Infections and infestations 10013023 Diphtheria PT
    14.0 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021569-58 Sponsor Protocol Number: 113948 Start Date*: 2010-11-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, double-blind, randomized, multicentre study to evaluate the safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine when administered to...
    Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10043376 Tetanus PT
    13.1 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    13.1 10021881 - Infections and infestations 10034738 Pertussis PT
    13.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    13.1 10021881 - Infections and infestations 10013023 Diphtheria PT
    13.1 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-001864-50 Sponsor Protocol Number: IIV-268 Start Date*: 2013-07-22
    Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands)
    Full Title: Long-term memory immunity against Bordetella pertussis in children 9 years of age who have been vaccinated with acellular pertussis vaccines: effect of an extra preadolescent acellular booster vacc...
    Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004495-34 Sponsor Protocol Number: iMAP2 Start Date*: 2014-03-11
    Sponsor Name:Public Health England
    Full Title: A randomised controlled trial comparing two pertussis-containing vaccines in pregnancy and vaccine responses in UK mothers and their infants (immunising Mums Against Pertussis, iMAP2)
    Medical condition: No medical condition or disease, instead responses to immunisations against pertussis (whooping cough) in mothers and against pertussis (whooping cough), tetanus, diphtheria, Hib, meningococcal C a...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10018065 - General disorders and administration site conditions 10059080 Vaccination site reaction PT
    16.1 10042613 - Surgical and medical procedures 10054175 Polio immunisation PT
    16.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    16.1 10042613 - Surgical and medical procedures 10069578 Pneumococcal immunisation PT
    16.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    16.1 100000004862 10047976 Whooping cough due to bordetella pertussis (B. pertussis) LLT
    16.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    16.1 10042613 - Surgical and medical procedures 10063021 Primary immunisation LLT
    16.1 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    16.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    16.1 10042613 - Surgical and medical procedures 10069533 Haemophilus influenzae type b immunisation PT
    16.1 10018065 - General disorders and administration site conditions 10069620 Vaccination site swelling PT
    16.1 10042613 - Surgical and medical procedures 10039244 Routine vaccination LLT
    16.1 10042613 - Surgical and medical procedures 10034101 Passive immunisation LLT
    16.1 10042613 - Surgical and medical procedures 10039243 Routine immunisation LLT
    16.1 10042613 - Surgical and medical procedures 10039242 Routine childhood immunisation LLT
    Population Age: Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001457-18 Sponsor Protocol Number: 6108K2-2000-ES Start Date*: 2008-12-15
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: Single-blind, Randomized, Phase 1/2 Trial of the Safety, Tolerability, and Immunogenicity of Meningococcal Group B rLP2086 Vaccine in Healthy Infants
    Medical condition: Healthy infant vaccination against Meningitis B
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027202 Meningitis bacterial LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005355-32 Sponsor Protocol Number: IIV-275 Start Date*: 2014-03-06
    Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands)
    Full Title: Memory response against Bordetella pertussis in adults: immunological effects of an acellular pertussis booster vaccination
    Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000645-31 Sponsor Protocol Number: 113264 Start Date*: 2016-06-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, partially double-blind, randomised, controlled, single-centre study to assess the immunogenicity and reactogenicity of three different formulations of GSK Biologicals’ DTPw-HBV-IPV/Hib ...
    Medical condition: Booster immunisation against poliomyelitis disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005309-18 Sponsor Protocol Number: V66_05 Start Date*: 2014-12-10
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Ph III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine Quinvaxem® (DTwP-Hib-HepB Vaccine) when Administered...
    Medical condition: Prophilaxis against diphtheria, tetanus, pertussis, hepatitis B and invasive Haemophilus influenzae type b disease.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA